BCX17725
Netherton Syndrome
Pre-Clinical/Phase 1Investigational
Key Facts
Indication
Netherton Syndrome
Phase
Pre-Clinical/Phase 1
Status
Investigational
Company
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a mission-driven, commercial-stage biotech focused on delivering first-in-class or best-in-class oral therapies for rare diseases with significant unmet need. Its strategic evolution from a discovery entity was cemented by the 2020 FDA approval of ORLADEYO® (berotralstat), a once-daily oral prophylactic for HAE, establishing a sustainable revenue base. The company leverages its proprietary structure-guided drug design platform to build a pipeline in HAE and complement-mediated diseases, aiming to deepen its market penetration and expand into new therapeutic areas like Netherton syndrome.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| ATR-12 | Azitra | Phase 1 |
| QRX003 (via Quoin Pharmaceuticals) | Skinvisible Pharmaceuticals | Clinical Trials |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| SXR1096 | Sixera Pharma | Phase 1 |
| KB104 | Krystal Biotech | Preclinical |
| QRX003 | Quoin Pharmaceuticals | Phase 2/3 |